A single signaling pathway controls whether immune cells attack or befriend cells they encounter while patrolling our bodies, ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on ...

This article explores how the role of regulatory T cells in immunological self-tolerance evolved from skepticism to Nobel ...

Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide.1 Despite therapeutic ...

Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company developing precision medicines that modulate regulatory T cells (Tregs) to restore immune balance, today announced dosing of the ...

Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care ...

This year's two Japanese Nobel Prize winners spoke at separate venues in Stockholm ahead of Wednesday's Nobel Prize award ...

This study provides useful insights into addressing the question of whether the prevalence of autoimmune disease could be driven by sex differences in the T cell receptor (TCR) repertoire, correlating ...

Avant Technologies Inc. ("Avant" or the "Company"), an emerging biotechnology company focused on developing cellbased therapies for diabetes and age-related disorders, today announced a newly ...

Ouster, Inc. ("Ouster" or the "Company"), a global leader in high-performance lidar sensors and intelligent software solutions that bring Physical AI to life across the automotive, industrial, ...

BioInvent International (STO:BINV)46% objective response rate (6 of 13 evaluable patients) and a 92% disease control rate (12 of 13) in relapsed/refractory CTCLImmune activation confirmed by CD8+ T ...